Insmed’s (INSM) “Buy” Rating Reiterated at HC Wainwright

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Thursday. They currently have a $35.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 6.09% from the company’s current price.

INSM has been the topic of a number of other reports. BidaskClub upgraded Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Cowen reiterated a “buy” rating and issued a $54.00 price objective on shares of Insmed in a report on Friday, November 3rd. ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Robert W. Baird restated a “positive” rating and set a $42.00 price target (up from $32.00) on shares of Insmed in a research note on Thursday. Finally, Zacks Investment Research cut Insmed from a “hold” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $35.75.

Insmed (NASDAQ:INSM) traded up $0.53 on Thursday, reaching $32.99. The company had a trading volume of 683,500 shares, compared to its average volume of 610,650. Insmed has a 12-month low of $11.49 and a 12-month high of $33.54. The firm has a market capitalization of $2,486.14, a PE ratio of -10.61 and a beta of 1.18. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13.

In other Insmed news, Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total transaction of $487,500.00. Following the transaction, the director now directly owns 71,131 shares in the company, valued at $2,311,757.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.03% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. purchased a new stake in shares of Insmed during the third quarter worth $232,000. BNP Paribas Arbitrage SA increased its position in shares of Insmed by 666.7% during the second quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 6,520 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Insmed during the second quarter worth $129,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Insmed during the third quarter worth $256,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Insmed during the third quarter worth $287,000. Institutional investors own 95.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/04/insmeds-insm-buy-rating-reiterated-at-hc-wainwright.html.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply